Literature DB >> 16433897

Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.

Elisabeth J Rook1, Jan M van Ree, Wim van den Brink, Michel J X Hillebrand, Alwin D R Huitema, Vincent M Hendriks, Jos H Beijnen.   

Abstract

A pharmacokinetic-pharmacodynamic study was performed in opioid-dependent patients in the Netherlands, who were currently treated with high doses of pharmaceutically prepared heroin on medical prescription. Besides intravenous heroin, heroin was prescribed for inhalation by "chasing the dragon" method. In this technique, heroin base is heated on aluminium foil, and heroin vapours are inhaled into the lungs. Not much is known about the pharmacokinetics profile and bioavailability of this specific administration method. Therefore, a study was performed on pharmacokinetics and pharmacodynamics of heroin inhalation and intravenous use. Eleven patients who injected heroin and 9 patients who inhaled heroin entered the study. They were on steady-state heroin treatment for at least 12 months. For safety reasons, there was no crossing-over between heroin injection or inhalation. In a double-blind randomised study, 67-100-150% of the regular heroin maintenance dose was administered to each patient. Maximal single heroin dose was 450 mg. Plasma concentrations of heroin and its metabolites 6-monoacetylmorphine, morphine and morphine-glucuronides were analysed using LC-MS-MS. Blood pressure, heart rate, skin temperature and reaction time were assessed. Furthermore, visual analogue scales regarding craving and appreciation of heroin effect were scored by the subjects. Both in inhaling and injecting patients, the areas under curve of heroin and all measured metabolites were linearly related to heroin dose. Mean C(max) of heroin and its metabolites were 2-6 times lower after inhalation, than after intravenous injection. Bioavailability (F) of heroin inhalation was estimated as 52% (95% CI 44-61%). Heroin was rapidly cleared from plasma. Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation. Heroin Cl and Vd were correlated to body weight (R(2) 15-19%). Morphine-glucuronides levels were inversely related to creatinine clearance. After heroin administration, the reaction time was significantly prolonged with 28+/-5.3 msec. in injecting and 13+/-4.9 msec. in inhaling patients. Cardiovascular changes were only mild after heroin administration. Craving-scores declined immediately after heroin administration in both administration groups. Subjective heroin effect was rated more positively in heroin inhaling than in injecting patients, despite the lower C(max) levels following heroin inhalation. In both groups, in this blinded study heroin dose increments were more appreciated than dose reductions. Increments of 50% of the regular heroin dose did not cause any serious side effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433897     DOI: 10.1111/j.1742-7843.2006.pto_233.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  32 in total

1.  Toxic leukoencephalopathy after intravenous heroin injection: a case with clinical and radiological reversibility.

Authors:  Corrado Villella; Raffaele Iorio; Gianluigi Conte; Anna Paola Batocchi; Pietro Bria
Journal:  J Neurol       Date:  2010-06-18       Impact factor: 4.849

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

4.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

5.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

6.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

7.  Supramolecular Sensors for Opiates and Their Metabolites.

Authors:  Elena G Shcherbakova; Ben Zhang; Samer Gozem; Tsuyoshi Minami; Peter Y Zavalij; Mariia Pushina; Lyle D Isaacs; Pavel Anzenbacher
Journal:  J Am Chem Soc       Date:  2017-09-08       Impact factor: 15.419

Review 8.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets.

Authors:  Ludwig Perger; Katharina M Rentsch; Gerd A Kullak-Ublick; Davide Verotta; Karin Fattinger
Journal:  Eur J Pharm Sci       Date:  2008-11-25       Impact factor: 4.384

10.  Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats.

Authors:  A Gottås; E L Øiestad; F Boix; V Vindenes; Å Ripel; C H Thaulow; J Mørland
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.